Physician profile
Kent L Mitchell
NPI 1619170453
$4,399.64
in general payments reported to CMS, 2019-2025
28 companies · $665 in 2025
The $665 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $645 · 2021: $696 · 2022: $724 · 2023: $416 · 2024: $484 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,920.45 | 2019-2025 | Proclaim, Eterna |
| Medtronic USA, INC. | $235.07 | 2019-2020 | |
| Nevro Corp. | $168.51 | 2019-2021 | |
| Pfizer INC. | $145.39 | 2019-2021 | |
| Nalu Medical, INC. | $142.26 | 2025 | Nalu Neurostimulation System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $114.08 | 2020-2025 | Relistor |
| Si-Bone, INC. | $106.88 | 2019-2025 | |
| Forte Bio-Pharma LLC | $74.36 | 2022 | |
| Painteq LLC | $54.08 | 2022-2024 | Painteq |
| Stryker Corporation | $53.07 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $46.94 | 2025 | |
| Biodelivery Sciences International, INC. | $44.22 | 2020 | |
| Interventional Pain Technologies INC. | $39.29 | 2021 | |
| Abbvie INC. | $31.85 | 2021-2024 | |
| Bolton Medical INC | $31.06 | 2024 | Treo Abdominal Stent-Graft System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $23.71 | 2023 | Tirosint, Licart |
| Collegium Pharmaceutical, INC. | $23.01 | 2019 | |
| Horizon Therapeutics Plc | $20.85 | 2022 | |
| Depuy Synthes Sales INC. | $16.09 | 2019 | |
| Tonix Medicines, INC. | $15.67 | 2025 | Tonmya |
| Spr Therapeutics, INC | $15.24 | 2024 | Sprint Pns System |
| Daiichi Sankyo INC. | $13.62 | 2019 | |
| Amgen INC. | $13.40 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.76 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.64 | 2020 | |
| Ferring Pharmaceuticals INC. | $11.81 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$48,200.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.